At OmniSeq®, our mission since 2015 has been simple: To help each cancer patient find and access the drug or trial that’s right for them. We do this through molecular sequencing and first-of-its-kind comprehensive immune profiling, as well as pharmaceutical services.
Through a collaboration with LabCorp®, we created and launched OmniSeq Advance℠, Immune Report Card®, OmniSeq Comprehensive® and MSI NGS℠. These innovative tools – which will be offered exclusively to U.S.-based physicians by Integrated Oncology, a member of the LabCorp Specialty Testing Group, and biopharmaceutical customers globally through Covance Drug Development – enable medical professionals to identify appropriate treatments specific to a patient’s cancer and immune profile.